

【4-9 メタアナリシス】

<b>CQ</b>		手術可能な浸潤性乳癌に対して術前化学療法+トラスツズマブは推奨されるか？																																																																										
<b>P</b>	手術可能な浸潤性乳癌	<b>I</b>	術前化学療法+トラスツズマブ																																																																									
<b>C</b>	術前化学療法	<b>O</b>	温存率の向上																																																																									
<b>研究デザイン</b>	RCT	<b>文献数</b>	3	<b>コード</b>	BuzdarAU 2005, 2010, Pierga JY 2010, ABCSG-24 2014																																																																							
<b>モデル</b>	ランダム効果	<b>方法</b>	Cochrane Review Manager Software (RevMan 5.3)																																																																									
<b>効果指標</b>	リスク比	<b>統合値</b>	0.93 ( 0.76 - 1.14 ) P= 0.51																																																																									
<b>Forest plot</b>	<table border="1"> <thead> <tr> <th rowspan="2">Study or Subgroup</th> <th colspan="2">with trastuzumab</th> <th colspan="2">without trastuzumab</th> <th rowspan="2">Weight</th> <th colspan="2">Risk Ratio</th> </tr> <tr> <th>Events</th> <th>Total</th> <th>Events</th> <th>Total</th> <th>M-H, Random, 95% CI</th> <th>M-H, Random, 95% CI</th> </tr> </thead> <tbody> <tr> <td>ABCSG-24 2014</td> <td>29</td> <td>44</td> <td>37</td> <td>49</td> <td>58.5%</td> <td>0.87</td> <td>[0.67, 1.14]</td> </tr> <tr> <td>Buzdar AU</td> <td>13</td> <td>23</td> <td>10</td> <td>19</td> <td>13.3%</td> <td>1.07</td> <td>[0.62, 1.87]</td> </tr> <tr> <td>Pierga JY 2010</td> <td>29</td> <td>62</td> <td>27</td> <td>58</td> <td>28.2%</td> <td>1.00</td> <td>[0.69, 1.47]</td> </tr> <tr> <td><b>Total (95% CI)</b></td> <td></td> <td><b>129</b></td> <td></td> <td><b>126</b></td> <td><b>100.0%</b></td> <td><b>0.93</b></td> <td><b>[0.76, 1.14]</b></td> </tr> <tr> <td colspan="2">Total events</td> <td>71</td> <td>74</td> <td colspan="4"></td> </tr> <tr> <td colspan="8">Heterogeneity: Tau<sup>2</sup> = 0.00; Chi<sup>2</sup> = 0.67, df = 2 (P = 0.72); I<sup>2</sup> = 0%</td> </tr> <tr> <td colspan="8">Test for overall effect: Z = 0.66 (P = 0.51)</td> </tr> </tbody> </table>						Study or Subgroup	with trastuzumab		without trastuzumab		Weight	Risk Ratio		Events	Total	Events	Total	M-H, Random, 95% CI	M-H, Random, 95% CI	ABCSG-24 2014	29	44	37	49	58.5%	0.87	[0.67, 1.14]	Buzdar AU	13	23	10	19	13.3%	1.07	[0.62, 1.87]	Pierga JY 2010	29	62	27	58	28.2%	1.00	[0.69, 1.47]	<b>Total (95% CI)</b>		<b>129</b>		<b>126</b>	<b>100.0%</b>	<b>0.93</b>	<b>[0.76, 1.14]</b>	Total events		71	74					Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 0.67, df = 2 (P = 0.72); I <sup>2</sup> = 0%								Test for overall effect: Z = 0.66 (P = 0.51)							
	Study or Subgroup	with trastuzumab		without trastuzumab		Weight		Risk Ratio																																																																				
Events		Total	Events	Total	M-H, Random, 95% CI		M-H, Random, 95% CI																																																																					
ABCSG-24 2014	29	44	37	49	58.5%	0.87	[0.67, 1.14]																																																																					
Buzdar AU	13	23	10	19	13.3%	1.07	[0.62, 1.87]																																																																					
Pierga JY 2010	29	62	27	58	28.2%	1.00	[0.69, 1.47]																																																																					
<b>Total (95% CI)</b>		<b>129</b>		<b>126</b>	<b>100.0%</b>	<b>0.93</b>	<b>[0.76, 1.14]</b>																																																																					
Total events		71	74																																																																									
Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 0.67, df = 2 (P = 0.72); I <sup>2</sup> = 0%																																																																												
Test for overall effect: Z = 0.66 (P = 0.51)																																																																												
コメント: 有意な差は認めなかった																																																																												
<b>Funnel plot</b>																																																																												
	コメント: 異質性なし																																																																											
<b>その他の解析</b>					コメント:																																																																							
メタリグレーション																																																																												
感度分析																																																																												

【4-9 メタアナリシス】

<b>CQ</b>		手術可能な浸潤性乳癌に対して術前化学療法+トラスツズマブは推奨されるか？																																																	
<b>P</b>	手術可能な浸潤性乳管癌	<b>I</b>	術前化学療法+トラスツズマブ																																																
<b>C</b>	術前化学療法	<b>O</b>	無病生存期間の延長																																																
<b>研究デザイン</b>	RCT	<b>文献数</b>	2	<b>コード</b>	NOAH 2010 BuzdarAU 2005																																														
<b>モデル</b>	ランダム効果	<b>方法</b>	Cochrane Review Manager Software (RevMan 5.3)																																																
<b>効果指標</b>	リスク比	<b>統合値</b>	0.54 ( 0.15 - 1.91 ) P= 0.34																																																
<b>Forest plot</b>	<table border="1"> <thead> <tr> <th rowspan="2">Study or Subgroup</th> <th colspan="2">with trastuzumab</th> <th colspan="2">without trastuzumab</th> <th rowspan="2">Weight</th> <th colspan="2">Risk Ratio</th> </tr> <tr> <th>Events</th> <th>Total</th> <th>Events</th> <th>Total</th> <th>M-H, Random, 95% CI</th> <th>M-H, Random, 95% CI</th> </tr> </thead> <tbody> <tr> <td>Buzdar AU</td> <td>0</td> <td>22</td> <td>3</td> <td>19</td> <td>15.5%</td> <td>0.12</td> <td>[0.01, 2.26]</td> </tr> <tr> <td>NOAH</td> <td>36</td> <td>117</td> <td>51</td> <td>118</td> <td>84.5%</td> <td>0.71</td> <td>[0.51, 1.00]</td> </tr> <tr> <td><b>Total (95% CI)</b></td> <td></td> <td><b>139</b></td> <td></td> <td><b>137</b></td> <td><b>100.0%</b></td> <td><b>0.54</b></td> <td><b>[0.15, 1.91]</b></td> </tr> <tr> <td>Total events</td> <td>36</td> <td></td> <td>54</td> <td></td> <td></td> <td></td> <td></td> </tr> </tbody> </table> <p>Heterogeneity: Tau<sup>2</sup> = 0.46; Chi<sup>2</sup> = 1.41, df = 1 (P = 0.23); I<sup>2</sup> = 29% Test for overall effect: Z = 0.95 (P = 0.34)</p>					Study or Subgroup	with trastuzumab		without trastuzumab		Weight	Risk Ratio		Events	Total	Events	Total	M-H, Random, 95% CI	M-H, Random, 95% CI	Buzdar AU	0	22	3	19	15.5%	0.12	[0.01, 2.26]	NOAH	36	117	51	118	84.5%	0.71	[0.51, 1.00]	<b>Total (95% CI)</b>		<b>139</b>		<b>137</b>	<b>100.0%</b>	<b>0.54</b>	<b>[0.15, 1.91]</b>	Total events	36		54				
Study or Subgroup	with trastuzumab		without trastuzumab		Weight		Risk Ratio																																												
	Events	Total	Events	Total		M-H, Random, 95% CI	M-H, Random, 95% CI																																												
Buzdar AU	0	22	3	19	15.5%	0.12	[0.01, 2.26]																																												
NOAH	36	117	51	118	84.5%	0.71	[0.51, 1.00]																																												
<b>Total (95% CI)</b>		<b>139</b>		<b>137</b>	<b>100.0%</b>	<b>0.54</b>	<b>[0.15, 1.91]</b>																																												
Total events	36		54																																																
	コメント: weightの高い試験は、術後には両群にtrastuzumabが使用されている(control群の17%) もう一つの試験は術後には共にTrastuzumabは使用されていない																																																		
<b>Funnel plot</b>																																																			
	コメント: 異質性なし																																																		
<b>その他の解析</b>					コメント:																																														
メタリグレッション																																																			
感度分析																																																			

【4-9 メタアナリシス】

<b>CQ</b>		手術可能な浸潤性乳癌に対して術前化学療法+トラスツズマブは推奨されるか？																																																							
<b>P</b>	手術可能な浸潤性乳管癌	<b>I</b>	術前化学療法+トラスツズマブ																																																						
<b>C</b>	術前化学療法	<b>O</b>	全生存率の改善																																																						
<b>研究デザイン</b>	RCT	<b>文献数</b>	1	<b>コード</b>	NOAH 2010																																																				
<b>モデル</b>	ランダム効果	<b>方法</b>	Cochrane Review Manager Software (RevMan 5.3)																																																						
<b>効果指標</b>	ハザード比	<b>統合値</b>	0.64 ( 0.33 - 1.25 ) P= 0.19																																																						
<b>Forest plot</b>	<table border="1"> <thead> <tr> <th rowspan="2">Study or Subgroup</th> <th colspan="2">with trastuzumab</th> <th colspan="2">without trastuzumab</th> <th rowspan="2">Weight</th> <th rowspan="2">Odds Ratio IV, Fixed, 95% CI</th> <th rowspan="2">Year</th> </tr> <tr> <th>Events</th> <th>Total</th> <th>Events</th> <th>Total</th> </tr> </thead> <tbody> <tr> <td>NOAH</td> <td>18</td> <td>117</td> <td>26</td> <td>118</td> <td>100.0%</td> <td>0.64 [0.33, 1.25]</td> <td>2010</td> </tr> <tr> <td>Total (95% CI)</td> <td></td> <td>117</td> <td>26</td> <td>118</td> <td>100.0%</td> <td>0.64 [0.33, 1.25]</td> <td></td> </tr> <tr> <td colspan="8">Total events: 18</td> </tr> <tr> <td colspan="8">Heterogeneity: Not applicable</td> </tr> <tr> <td colspan="8">Test for overall effect: Z = 1.30 (P = 0.19)</td> </tr> </tbody> </table> <p>コメント: 一つの試験の結果しかない、術前にtrastuzumabを使用しなかった群の17%では術後にtrastuzumabが使用されている</p>					Study or Subgroup	with trastuzumab		without trastuzumab		Weight	Odds Ratio IV, Fixed, 95% CI	Year	Events	Total	Events	Total	NOAH	18	117	26	118	100.0%	0.64 [0.33, 1.25]	2010	Total (95% CI)		117	26	118	100.0%	0.64 [0.33, 1.25]		Total events: 18								Heterogeneity: Not applicable								Test for overall effect: Z = 1.30 (P = 0.19)							
Study or Subgroup	with trastuzumab		without trastuzumab		Weight		Odds Ratio IV, Fixed, 95% CI	Year																																																	
	Events	Total	Events	Total																																																					
NOAH	18	117	26	118	100.0%	0.64 [0.33, 1.25]	2010																																																		
Total (95% CI)		117	26	118	100.0%	0.64 [0.33, 1.25]																																																			
Total events: 18																																																									
Heterogeneity: Not applicable																																																									
Test for overall effect: Z = 1.30 (P = 0.19)																																																									
<b>Funnel plot</b>	<p>コメント: RCTは一つのためFunnel plotはなし</p>																																																								
<b>その他の解析</b>					コメント:																																																				
メタリグレーション																																																									
感度分析																																																									

【4-9 メタアナリシス】

<b>CQ</b>		手術可能な浸潤性乳癌に対して術前化学療法+トラスツズマブは推奨されるか？																																																															
<b>P</b>	手術可能な浸潤性乳管癌	<b>I</b>	術前化学療法+トラスツズマブ																																																														
<b>C</b>	術前化学療法	<b>O</b>	心毒性の増加																																																														
<b>研究デザイン</b>	RCT	<b>文献数</b>	3	<b>コード</b>	BuzdarAU 2005 , ABCSG-24 2014, NOAH2010																																																												
<b>モデル</b>	ランダム効果	<b>方法</b>	Cochrane Review Manager Software (RevMan 5.3)																																																														
<b>効果指標</b>	リスク比	<b>統合値</b>	1.54 ( 0.66 - 3.62 ) P= 0.32																																																														
<b>Forest plot</b>	<table border="1"> <thead> <tr> <th rowspan="2">Study or Subgroup</th> <th colspan="2">with trastuzumab</th> <th colspan="2">without trastuzumab</th> <th rowspan="2">Weight</th> <th rowspan="2">Risk Ratio M-H, Random, 95% CI</th> </tr> <tr> <th>Events</th> <th>Total</th> <th>Events</th> <th>Total</th> </tr> </thead> <tbody> <tr> <td>ABCSG-24 2014</td> <td>3</td> <td>21</td> <td>1</td> <td>25</td> <td>15.2%</td> <td>3.57 [0.40, 31.83]</td> </tr> <tr> <td>Buzdar AU</td> <td>7</td> <td>23</td> <td>5</td> <td>19</td> <td>76.8%</td> <td>1.16 [0.44, 3.06]</td> </tr> <tr> <td>NOAH</td> <td>2</td> <td>115</td> <td>0</td> <td>113</td> <td>8.0%</td> <td>4.91 [0.24, 101.23]</td> </tr> <tr> <td><b>Total (95% CI)</b></td> <td></td> <td><b>159</b></td> <td></td> <td><b>157</b></td> <td><b>100.0%</b></td> <td><b>1.54 [0.66, 3.62]</b></td> </tr> <tr> <td>Total events</td> <td>12</td> <td></td> <td>6</td> <td></td> <td></td> <td></td> </tr> <tr> <td colspan="7">Heterogeneity: Tau<sup>2</sup> = 0.00; Chi<sup>2</sup> = 1.55, df = 2 (P = 0.46); I<sup>2</sup> = 0%</td> </tr> <tr> <td colspan="7">Test for overall effect: Z = 0.99 (P = 0.32)</td> </tr> </tbody> </table>				Study or Subgroup	with trastuzumab		without trastuzumab		Weight	Risk Ratio M-H, Random, 95% CI	Events	Total	Events	Total	ABCSG-24 2014	3	21	1	25	15.2%	3.57 [0.40, 31.83]	Buzdar AU	7	23	5	19	76.8%	1.16 [0.44, 3.06]	NOAH	2	115	0	113	8.0%	4.91 [0.24, 101.23]	<b>Total (95% CI)</b>		<b>159</b>		<b>157</b>	<b>100.0%</b>	<b>1.54 [0.66, 3.62]</b>	Total events	12		6				Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 1.55, df = 2 (P = 0.46); I <sup>2</sup> = 0%							Test for overall effect: Z = 0.99 (P = 0.32)							<p>コメント: イベント数が少なく、有意な差は認めなかった</p>
Study or Subgroup	with trastuzumab		without trastuzumab			Weight	Risk Ratio M-H, Random, 95% CI																																																										
	Events	Total	Events	Total																																																													
ABCSG-24 2014	3	21	1	25	15.2%	3.57 [0.40, 31.83]																																																											
Buzdar AU	7	23	5	19	76.8%	1.16 [0.44, 3.06]																																																											
NOAH	2	115	0	113	8.0%	4.91 [0.24, 101.23]																																																											
<b>Total (95% CI)</b>		<b>159</b>		<b>157</b>	<b>100.0%</b>	<b>1.54 [0.66, 3.62]</b>																																																											
Total events	12		6																																																														
Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 1.55, df = 2 (P = 0.46); I <sup>2</sup> = 0%																																																																	
Test for overall effect: Z = 0.99 (P = 0.32)																																																																	
<b>Funnel plot</b>					<p>コメント: 異質性なし</p>																																																												
<b>その他の解析</b>				コメント:																																																													
メタリグレーション																																																																	
感度分析																																																																	

【4-9 メタアナリシス】

<b>CQ</b>		手術可能な浸潤性乳癌に対して術前化学療法+トラスツズマブは推奨されるか？																																																																																		
<b>P</b>	手術可能な浸潤性乳癌	<b>I</b>	術前化学療法+トラスツズマブ																																																																																	
<b>C</b>	術前化学療法	<b>O</b>	pCR率の上昇																																																																																	
<b>研究デザイン</b>	RCT	<b>文献数</b>	4	<b>コード</b>	NOAH 2010 BuzdarAU 2005 Pierga JY 2010, ABCSG-24 2014																																																																															
<b>モデル</b>	ランダム効果	<b>方法</b>	Cochrane Review Manager Software (RevMan 5.3)																																																																																	
<b>効果指標</b>	リスク比	<b>統合値</b>	1.77 ( 1.32 - 2.36 ) P= 0.0001																																																																																	
<b>Forest plot</b>	<table border="1"> <thead> <tr> <th rowspan="2">Study or Subgroup</th> <th colspan="2">with trastuzumab</th> <th colspan="2">without trastuzumab</th> <th rowspan="2">Weight</th> <th colspan="2">Risk Ratio</th> </tr> <tr> <th>Events</th> <th>Total</th> <th>Events</th> <th>Total</th> <th>M-H, Random, 95% CI</th> <th>M-H, Random, 95% CI</th> </tr> </thead> <tbody> <tr> <td>ABCSG-24 2014</td> <td>17</td> <td>44</td> <td>13</td> <td>49</td> <td>23.7%</td> <td>1.46</td> <td>[0.80, 2.64]</td> </tr> <tr> <td>Buzdar AU</td> <td>15</td> <td>23</td> <td>5</td> <td>19</td> <td>12.9%</td> <td>2.48</td> <td>[1.10, 5.57]</td> </tr> <tr> <td>NOAH</td> <td>45</td> <td>117</td> <td>23</td> <td>118</td> <td>45.1%</td> <td>1.97</td> <td>[1.28, 3.04]</td> </tr> <tr> <td>Pierga JY 2010</td> <td>16</td> <td>62</td> <td>11</td> <td>58</td> <td>18.3%</td> <td>1.36</td> <td>[0.69, 2.68]</td> </tr> <tr> <td><b>Total (95% CI)</b></td> <td></td> <td><b>246</b></td> <td></td> <td><b>244</b></td> <td><b>100.0%</b></td> <td><b>1.77</b></td> <td><b>[1.32, 2.36]</b></td> </tr> <tr> <td colspan="2">Total events</td> <td>93</td> <td>52</td> <td colspan="3"></td> <td colspan="2"></td> </tr> <tr> <td colspan="8">Heterogeneity: Tau<sup>2</sup> = 0.00; Chi<sup>2</sup> = 1.89, df = 3 (P = 0.59); I<sup>2</sup> = 0%</td> </tr> <tr> <td colspan="8">Test for overall effect: Z = 3.84 (P = 0.0001)</td> </tr> </tbody> </table>					Study or Subgroup	with trastuzumab		without trastuzumab		Weight	Risk Ratio		Events	Total	Events	Total	M-H, Random, 95% CI	M-H, Random, 95% CI	ABCSG-24 2014	17	44	13	49	23.7%	1.46	[0.80, 2.64]	Buzdar AU	15	23	5	19	12.9%	2.48	[1.10, 5.57]	NOAH	45	117	23	118	45.1%	1.97	[1.28, 3.04]	Pierga JY 2010	16	62	11	58	18.3%	1.36	[0.69, 2.68]	<b>Total (95% CI)</b>		<b>246</b>		<b>244</b>	<b>100.0%</b>	<b>1.77</b>	<b>[1.32, 2.36]</b>	Total events		93	52						Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 1.89, df = 3 (P = 0.59); I <sup>2</sup> = 0%								Test for overall effect: Z = 3.84 (P = 0.0001)							
	Study or Subgroup	with trastuzumab		without trastuzumab			Weight	Risk Ratio																																																																												
Events		Total	Events	Total	M-H, Random, 95% CI	M-H, Random, 95% CI																																																																														
ABCSG-24 2014	17	44	13	49	23.7%	1.46	[0.80, 2.64]																																																																													
Buzdar AU	15	23	5	19	12.9%	2.48	[1.10, 5.57]																																																																													
NOAH	45	117	23	118	45.1%	1.97	[1.28, 3.04]																																																																													
Pierga JY 2010	16	62	11	58	18.3%	1.36	[0.69, 2.68]																																																																													
<b>Total (95% CI)</b>		<b>246</b>		<b>244</b>	<b>100.0%</b>	<b>1.77</b>	<b>[1.32, 2.36]</b>																																																																													
Total events		93	52																																																																																	
Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 1.89, df = 3 (P = 0.59); I <sup>2</sup> = 0%																																																																																				
Test for overall effect: Z = 3.84 (P = 0.0001)																																																																																				
<p>コメント: 有意な差を認める.</p>																																																																																				
<b>Funnel plot</b>																																																																																				
	<p>コメント: 異質性なし</p>																																																																																			
<b>その他の解析</b>					コメント:																																																																															
メタリグレーション																																																																																				
感度分析																																																																																				